ABSTRACT

COVID-19 emerges to produce genetic changes in platelets of blood. Platelets accumulated more easily in the blood of COVID-19 patient and they are more correlated with a greater risk of thrombus or blood clotting, which can cause of heart attack, stroke, organ failure and other serious complications in a number of patients, mostly among those with underlying disorders such as diabetes, obesity, or high blood pressure. Blood viscosity is directly correlated with systolic and diastolic blood pressure. Venous hematocrit and plasma viscosity are higher in the hypertensive patients. To reduce the blood-viscosity of such patient a regular dose of hydroxychloroquine with azithromycin can be given to increase flow of blood in blood vessels by building the blood slighter viscous than earlier and to reduce the infection of virus in the respiratory system. The blood flow of patients with the greater viscosity can be reduced by reducing the viscosity of plasma. Hydroxychloroquine is a glucose lowering drug which means it helps to lower the blood sugar in the patient; hence it works on lowering the blood viscosity, whereas the azithromycin is an antibiotic used to treat the respiratory infections. In presented work efforts have been initiated to investigate some result for behavior of blood flow in blood vessels and the significance of hydroxychloroquine with azithromycin for COVID-19 patient. At the end the numerical demonstration has been given to deliver the outcomes for the blood flow, pressure and viscosity. The findings of this research work may possibly assist in the treatment and diagnosis of cardiovascular disorders as well as COVID-19 patient. Keywords: Stenosis, Blood flow, Blood vessels, Viscosity, Hydroxychloroquine, Azithromycin
Publication date: 01/07/21

https://ijbpas.com/pdf/2021/July/MS_IJBPAS_2021_5530.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2021/10.7.5530